3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
5
Neoplasms
4
Prostatic Neoplasms
3
Oligodendroglioma
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Melanoma
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Anus Neoplasms
2
Weight Loss
1
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Thrombocytopenia
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Splenomegaly
1
Skin Neoplasms
1
Interventions
Nivolumab
13
Surveys and Questionnaires
6
Ipilimumab
6
linrodostat
5
Standard of Care
5
Paclitaxel
5
Bevacizumab
5
Sirolimus
4
Pemetrexed
4
Interviews as Topic
4
Gemcitabine
4
Docetaxel
4
ARRY-334543
4
temsirolimus
3
relatlimab
3
Erlotinib Hydrochloride
3
Cetuximab
3
Carboplatin
3
regorafenib
2
anlotinib
2
abemaciclib
2
Vorinostat
2
Trastuzumab
2
Sorafenib
2
N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Dasatinib
2
Cyclophosphamide
2
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Cancer
×
Quality of Life
×
Clear all
NCT01444157
2014-07-18
FamCope
Bispebjerg Hospital
Phase 3
Completed
700 enrolled